Cargando…

Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment

Haploidentical stem cell transplantation (haplo SCT) in Stage IV neuroblastoma relapsed patients has been proven efficacious, while immunotherapy utilizing the anti-GD2 antibody dinutuximab beta has become a standard treatment for neuroblastoma. The combinatorial therapy of haplo SCT and dinutuximab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seitz, Christian Martin, Flaadt, Tim, Mezger, Markus, Lang, Anne-Marie, Michaelis, Sebastian, Katz, Marie, Syring, Desireé, Joechner, Alexander, Rabsteyn, Armin, Siebert, Nikolai, Troschke-Meurer, Sascha, Zumpe, Maxi, Lode, Holger N., Yang, Sile F., Atar, Daniel, Mast, Anna-Sophia, Scheuermann, Sophia, Heubach, Florian, Handgretinger, Rupert, Lang, Peter, Schlegel, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339919/ https://www.ncbi.nlm.nih.gov/pubmed/34367149 http://dx.doi.org/10.3389/fimmu.2021.690467

Ejemplares similares

Reduction of CD11b(+) myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD(2) antibody ch14.18/CHO
por: Siebert, Nikolai, et al.
Publicado: (2020)

Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2
por: Troschke-Meurer, Sascha, et al.
Publicado: (2019)

Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice
por: Marx, Madlen, et al.
Publicado: (2018)

Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3)
por: Arendt, A.-M., et al.
Publicado: (2023)

Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial
por: Siebert, Nikolai, et al.
Publicado: (2018)

The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD(2) Antibody Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2022)

Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study
por: Lode, Holger N., et al.
Publicado: (2023)

Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
por: Cicek, Filiz, et al.
Publicado: (2020)

Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2023)

Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models
por: Troschke-Meurer, Sascha, et al.
Publicado: (2023)

Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments
por: Klingel, Leah, et al.
Publicado: (2022)

Haploidentical hematopoietic stem cell transplantation as individual treatment option in pediatric patients with very high-risk sarcomas
por: Eichholz, Thomas, et al.
Publicado: (2023)

Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
por: Pers, Yves-Marie, et al.
Publicado: (2011)

Development of the automated immunomonitoring system
por: Osawa, Ryuji, et al.
Publicado: (2014)

From Immunomonitoring to Immune Intervention
por: Toubert, Antoine, et al.
Publicado: (2015)

Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy
por: Lode, Holger N., et al.
Publicado: (2023)

Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas
por: Atar, Daniel, et al.
Publicado: (2022)

Multimodal Therapy with Consolidating Haploidentical Stem Cell Transplantation and Dinutuximab Beta for Patients with High-Risk Neuroblastoma and Central Nervous System Relapse
por: Flaadt, Tim, et al.
Publicado: (2023)

Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2021)

Strategies for Immunomonitoring after Vaccination and during Infection
por: Adam, Lucille, et al.
Publicado: (2021)

BCL11B depletion induces the development of highly cytotoxic innate T cells out of IL-15 stimulated peripheral blood αβ CD8+ T cells
por: Forkel, Hannes, et al.
Publicado: (2022)

In vitro immunomonitoring of insect venom-allergic patients on immunotherapy
por: Cifuentes, Liliana, et al.
Publicado: (2014)

Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease
por: Tighe, Donal, et al.
Publicado: (2017)

TNF Blocking Therapies and Immunomonitoring in Patients with Inflammatory Bowel Disease
por: Altwegg, Romain, et al.
Publicado: (2014)

Immunomonitoring of Human Breast Milk Cells During HCMV-Reactivation
por: Lazar, Katrin, et al.
Publicado: (2021)

Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting
por: Seitz, Christian M., et al.
Publicado: (2021)

Lipofection with Synthetic mRNA as a Simple Method for T-Cell Immunomonitoring
por: Jarzebska, Natalia Teresa, et al.
Publicado: (2021)

Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial
por: Flaadt, Tim, et al.
Publicado: (2023)

Association of Thrombomodulin Gene C1418T Polymorphism with Susceptibility to Kawasaki Disease in Chinese Children
por: Lu, Yapeng, et al.
Publicado: (2018)

Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
por: Simon, Thorsten, et al.
Publicado: (2011)

Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19
por: Rodriguez, Lucie, et al.
Publicado: (2020)

Treatment of graft failure with TNI‐based reconditioning and haploidentical stem cells in paediatric patients
por: Teltschik, Heiko‐Manuel, et al.
Publicado: (2016)

Eradication of Pulmonary Aspergillosis in an Adolescent Patient Undergoing Three Allogeneic Stem Cell Transplantations for Acute Lymphoblastic Leukemia
por: Döring, Michaela, et al.
Publicado: (2012)

The Premalignant Ancestor Cell of t(14;18)(+) Lymphoma
por: Brisou, Gabriel, et al.
Publicado: (2021)

Identification of new MUC1 epitopes using HLA-transgenic animals: implication for immunomonitoring
por: Scheikl-Gatard, Tanja, et al.
Publicado: (2017)

Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD(2) Antibody
por: Siebert, Nikolai, et al.
Publicado: (2014)

Generation and Characterization of a Human/Mouse Chimeric GD(2)-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma
por: Eger, Christin, et al.
Publicado: (2016)

Development of CAR T Cell Therapy in Children—A Comprehensive Overview
por: Boettcher, Michael, et al.
Publicado: (2022)

Defibrotide for the Treatment of Pediatric Inflammatory Multisystem Syndrome Temporally Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 2 Pediatric Patients
por: Lang, Peter, et al.
Publicado: (2020)

NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML
por: Schlegel, Patrick, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_pgcfj9ojjlsidc7o3vm1mb9u16